報價延遲最少15分鐘:2025/07/09 20:20 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.64 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.06/-1.32
|
|
企業價值
160.94M
|
| 資產負債 |
|
每股賬面淨值
2.49
|
| 現金流量 |
|
現金流量率
0.09
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/09 20:20 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535. |